Weihai, Shandong, China
The XINSORB® Bioresorbable Sirolimus-eluting Scaffold developed by HUAAN company under WEGO group is approved by the National Medical Products Administration (NMPA) and successfully launched to domestic market. It is the first sirolimus-eluting BRS with independent intellectual property rights in China.
The XINSORB® Bioresorbable Scaffold is jointly researched by WEGO and a team led by Professor Junbo Ge, a member of the Chinese Academy of Sciences and a professor of Zhongshan Hospital affiliated to Fudan University.
The XINSORB® Scaffold is fully bioresorbable with polymeric polylactic platform for sirolimus eluting and will be completely degraded and absorbed within 2 to 3 years after in-human stenting.